Abbisko Therapeutics recently reported that its self-developed small molecule FGFR4 inhibitor ABSK012, aimed at drug-resistant mutations, has received FDA approval to begin phase I human trials with advanced solid tumor patients.

MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).

Molecular Templates has commenced dosing in Phase 1 trial of MT-8421, a unique engineered toxin body targeting CTLA-4, for treating advanced solid tumors.

TTerns Pharmaceuticals reported the initial participant administration in Phase 1 Clinical Testing of TERN-601 Oral GLP-1 Receptor Agonist, a potential treatment for obesity.

Clinical-stage biopharmaceutical firm Inhibrx declared initial Phase 1 trial results for INBRX-109, used with Irinotecan and Temozolomide, to treat advanced, non-removable Ewing sarcoma. The trial focused on efficacy and safety.

IDRx, Inc. has reported initial clinical results from its ongoing Phase 1 StrateGIST trial of IDRX-42. This trial is for patients with metastatic and/or inoperable gastrointestinal stromal tumors who have previously received at least one tyrosine kinase inhibitor therapy regime, now testing a higher dosage.

Fresenius Kabi made an announcement about the introduction of Tyenne®, its tocilizumab biosimilar which references the RoActemra® (tocilizumab) in the European Union.

Recent trial findings of Junshi Biosciences' Toripalimab and Cetuximab combo for treating R/M-HNSCC were shared at the 38th annual SITC meeting in 2023.

Innovent Biologics reported two clinical research outcomes at the 2023 AAO annual meeting on Nov 6, 2023. These include the Phase 2 clinical data for IBI302, an anti-VEGF-anti-complement dual target drug for nAMD treatment, and Phase 1 clinical data for IBI324, an anti-VEGF-A/Ang-2 bispecific antibody for DME treatment.

Otsuka Pharmaceutical and Visterra recently reported that the full Phase II trial results for sibeprenlimab (VIS649), a treatment for IgA nephropathy, have been published in the NEJM.

HuidaGene Therapeutics, a global oncology-focused biotech company, has announced its first treatment in its multinational HG004 gene therapy study (STAR study). This phase 1/2a investigation uses CRISPR-influenced programmable genomic drugs to potentially treat inherited retinal dystrophies caused by RPE65 gene mutations.

Novartis reported FDA's approval of Cosentyx® (secukinumab) for the management of moderate to extreme hidradenitis suppurativa in adult patients.